Protein–protein interactions (PPIs) are implicated in the majority of cellular processes by
enabling and regulating the function of individual proteins. Thus, PPIs represent high-value …

Intracellular protein–protein interactions (PPIs) are challenging targets for traditional drug
modalities. Macrocyclic peptides (MPs) prove highly effective PPI inhibitors in vitro and can …

Biomacromolecules are highly promising therapeutic modalities to treat various diseases.
However, they suffer from poor cellular membrane permeability, limiting their access to …

We report the discovery of sulanemadlin (ALRN-6924), the first cell-permeating, stabilized α-
helical peptide to enter clinical trials. ALRN-6924 is a “stapled peptide” that mimics the N …

The LC3/GABARAP family of proteins is involved in nearly every stage of autophagy.
Inhibition of LC3/GABARAP proteins is a promising approach to blocking autophagy, which …

Although stapled α-helical peptides can address challenging targets, their advancement is
impeded by poor understandings for making them cell permeable while avoiding off-target …

Two decades after their discovery, stapled peptide methodologies have evolved to a point
where they can be used with confidence to generate therapeutic leads. Research groups …

The biggest obstacles in the application of marine peptides are two-fold, as in the case of
non-marine plant and animal-derived bioactive peptides: elucidating correlation between …

Macrocyclic peptides open new opportunities to target intracellular protein–protein
interactions (PPIs) that are often considered nondruggable by traditional small molecules …

Macrocyclic peptides show promise in targeting high-value therapeutically relevant binding
sites due to their high affinity and specificity. However, their clinical application is often …